Its development marks a strategic pivot toward oral-first therapeutic models, potentially redefining the landscape of metabolic disease management while alleviating global supply chain limitations
The following side effects reported are: Very common: may affect more than 1 in 10 people Feeling sick (nausea), being sick (vomiting), diarrhoea, constipation, headache, abdominal pain and fatigue usually go away after a few days or weeks
The National Weight Control Registry, which tracks individuals who have maintained significant weight loss (30 pounds for 1 year), identifies common characteristics among successful maintainers
Weight loss injections such as semaglutide (Wegovy) and liraglutide (Saxenda) are increasingly prescribed for weight management in the UK, but their use in people with Crohn's disease requires careful consideration
Prioritizing both helps you stay strong and energized after a meal